Literature DB >> 9342771

Effects of long-term administration of hypericum extracts on the affinity and density of the central serotonergic 5-HT1 A and 5-HT2 A receptors.

R Teufel-Mayer1, J Gleitz.   

Abstract

Extracts of St. John's wort, Hypericum perforatum L. (Hypericaceae), are used as a phytotherapeutic antidepressant. A number of clinical studies demonstrate that their antidepressive potency is comparable to tricyclic antidepressants (TCA). Although the therapeutic effect of hypericum extracts is well documented, very little is known about the molecular mode of action. As the improvement of the depressive symptoms with both TCA and hypericum extracts only occurs significantly after a lag phase of 10 to 14 days, it is assumed that the medication causes long-term adaptations within the central nervous system. In this context, serotonergic (5-HT) receptors are of special interest. Therefore, we investigated possible alterations in affinity and density of 5-HT1 A and 5-HT2 A receptors caused by long-term treatment of rats with St. John's wort. The brain without cerebellum and brain stem of rats, treated daily for 26 weeks with a commercially available hypericum extract (2700 mg/kg LI 160) were used for membrane preparations. Affinity (KD) and amount (Bmax) of serotonergic receptors were determined by employing receptor binding assays using 3 H-8-OH-DPAT and 3H-Ketanserin as selective radioligands for the 5-HT1 A and the 5-HT2 A receptors, respectively. We found that in hypericum-treated rats the number of both 5-HT1 A and 5-HT2 A receptors were significantly increased by 50% compared to controls, whereas the affinity of both serotonergic receptors remained unaltered. The data suggest an upregulation of 5-HT1 A and 5-HT2 A receptors due to prolonged administration of hypericum extracts. These results are consistent with a modification of the expression levels of serotonergic receptors caused by synthetic antidepressants.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9342771     DOI: 10.1055/s-2007-979530

Source DB:  PubMed          Journal:  Pharmacopsychiatry        ISSN: 0176-3679            Impact factor:   5.788


  8 in total

1.  Autoradiographic quantification of neurochemical markers of serotonin, dopamine and opioid systems in rat brain mesolimbic regions following chronic St John's wort treatment.

Authors:  Feng Chen; Amir H Rezvani; Andrew J Lawrence
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-01-23       Impact factor: 3.000

2.  Mania and Psychosis Associated with St. John's Wort and Ginseng.

Authors:  Kaustubh G Joshi; Matthew D Faubion
Journal:  Psychiatry (Edgmont)       Date:  2005-09

3.  St. John's Wort enhances the synaptic activity of the nucleus of the solitary tract.

Authors:  Katie M Vance; David M Ribnicky; Gerlinda E Hermann; Richard C Rogers
Journal:  Nutrition       Date:  2014-02-28       Impact factor: 4.008

4.  The efficacy of Hypericum perforatum (St John's wort) for the treatment of premenstrual syndrome: a randomized, double-blind, placebo-controlled trial.

Authors:  Sarah Canning; Mitch Waterman; Nic Orsi; Julie Ayres; Nigel Simpson; Louise Dye
Journal:  CNS Drugs       Date:  2010-03       Impact factor: 5.749

5.  Update and critique of natural remedies as antidepressant treatments.

Authors:  David Mischoulon
Journal:  Obstet Gynecol Clin North Am       Date:  2009-12       Impact factor: 2.844

Review 6.  Mechanism of action of St John's wort in depression : what is known?

Authors:  Veronika Butterweck
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

7.  Alleviation by Hypericum perforatum of the stress-induced impairment of spatial working memory in rats.

Authors:  Emil Trofimiuk; Jan J Braszko
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-12-19       Impact factor: 3.000

8.  St. John's Wort protein, p27SJ, regulates the MCP-1 promoter.

Authors:  Ruma Mukerjee; Satish L Deshmane; Nune Darbinian; Marta Czernik; Kamel Khalili; Shohreh Amini; Bassel E Sawaya
Journal:  Mol Immunol       Date:  2008-07-22       Impact factor: 4.407

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.